A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
Completed · Phase 1/Phase 2
Conditions studied: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
In brief
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX® (cetuximab) in adults with recurrent and/or metastatic solid tumors.
Key facts
- Study ID
- NCT04474470
- Run by
- TyrNovo Ltd.
- People needed
- 52
- Starts
- 2020-09-03
- Expected to finish
- 2024-05-08
- Last updated by the study team
- 2024-09-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Cancer Associates for Research and Excellence — Encinitas, California, United States
- The Angeles Clinic and Research Institute — Los Angeles, California, United States
- UCSD Moores Cancer Center — San Diego, California, United States
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia, United States
- The University of Chicago and Biological Sciences — Chicago, Illinois, United States
- Ochsner Clinic Foundation — New Orleans, Louisiana, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Hadassah University Medical Center — Jerusalem, Israel
- Rabin Medical Center — Petah Tikva, Israel
- Sourasky Medical Center — Tel Aviv, Israel
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.